AMPK ß1 reduces tumor progression and improves survival in p53 null mice by Houde, Vanessa P. et al.
AMPK b1 reduces tumor progression and improves
survival in p53 null mice
Vanessa P. Houde1,2, Sara Donzelli3, Andrea Sacconi3, Sandra Galic4, Joanne A. Hammill5,
Jonathan L. Bramson5, Robert A. Foster6, Theodoros Tsakiridis1, Bruce E. Kemp4,7, Giuseppe
Grasso3, Giovanni Blandino1,3, Paola Muti1 and Gregory R. Steinberg2,8
1 Department of Oncology, McMaster University, Hamilton, Canada
2 Department of Medicine, McMaster University, Hamilton, Canada
3 Oncogenomic and Epigenetic Unit, Italian National Cancer Institute ‘Regina Elena’, Rome, Italy
4 St. Vincent’s Institute of Medical Research and Department of Medicine, University of Melbourne, Australia
5 Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Canada
6 Department of Pathobiology, Ontario Veterinary College, University of Guelph, Canada
7 Mary MacKillop Institute for Health Research Australian Catholic University, Fitzroy, Australia
8 Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Canada
Keywords
ACC; metabolism; cancer; lipogenesis
Correspondence
G. R. Steinberg, Division of Endocrinology
and Metabolism, Department of Medicine,
McMaster University, 1280 Main St. West,
Hamilton, Ontario, L8N 3Z5, Canada
Tel: 905 525 9140, ext. 21691
E-mail: gsteinberg@mcmaster.ca
(Received 6 February 2017, revised 15 May
2017, accepted 16 May 2017, available
online 28 June 2017)
doi:10.1002/1878-0261.12079
The AMP-activated protein kinase (AMPK) is a heterotrimeric protein
complex that is an important sensor of cellular energy status. Reduced
expression of the AMPK b1 isoform has been linked to reduced survival in
different cancers, but whether this accelerates tumor progression and the
potential mechanism mediating these effects are not known. Furthermore,
it is unknown whether AMPK b1 is implicated in tumorigenesis, and if so,
what tissues may be most sensitive. In the current study, we find that in
the absence of the tumor suppressor p53, germline genetic deletion of
AMPK b1 accelerates the appearance of a T-cell lymphoma that reduces
lifespan compared to p53 deficiency alone. This increased tumorigenesis is
linked to increases in interleukin-1b (IL1b), reductions in acetyl-CoA car-
boxylase (ACC) phosphorylation, and elevated lipogenesis. Collectively,
these data indicate that reductions in the AMPK b1 subunit accelerate the
development of T-cell lymphoma, suggesting that therapies targeting this
AMPK subunit or inhibiting lipogenesis may be effective for limiting the
proliferation of p53-mutant tumors.
1. Introduction
While it is now established that obesity and diabetes
can increase the risk of developing many types of can-
cer, the molecular signals that collaborate with onco-
genes to accelerate tumorigenesis under conditions of
nutrient excess are still not fully understood. The
AMP-activated protein kinase (AMPK) is an a, b, c
heterotrimer that senses changes in cellular energy sta-
tus, and whose activity is reduced under conditions of
nutrient surplus such as obesity and diabetes (Ruder-
man et al., 2013; Steinberg and Kemp, 2009). AMPK
activation by the upstream AMPK kinase LKB1
causes regulation of multiple branches of cellular
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metabolism that may be important for limiting cancer
cell proliferation (Mihaylova and Shaw, 2011). This
involves the inhibition of energy-consuming processes
such as fatty acid and protein biosynthesis, while
increasing catabolism by promoting autophagy and
fatty acid oxidation (Carling et al., 2012; Faubert
et al., 2015; Mihaylova and Shaw, 2011). In addition
to direct regulation of key metabolic checkpoints,
AMPK may also inhibit tumorigenesis through upreg-
ulation of transcription factors such as the tumor sup-
pressor p53, which is mutated in approximately 80%
of all cancers (He et al., 2014; Jones et al., 2005; Lee
et al., 2012). Mutation or genetic deficiency of p53
may also act to suppress AMPK activity (Zhou et al.,
2014), suggesting that the activities of p53 and AMPK
may be intimately linked to match energy availability
with cell proliferation (Adamovich et al., 2014). While
many studies have examined the interaction between
AMPK and the tumor suppressor p53 in cultured cells,
the importance of this pathway to tumorigenesis has
not been studied in vivo.
Increases in fatty acid synthesis are required to sus-
tain rapid proliferation in many types of cancer [for
review, see (Hanahan and Weinberg, 2011; Hirschey
et al., 2015)] including prostate and non-small-cell lung
cancer (NSCLC) (Shah et al., 2016; Svensson et al.,
2016; Villani et al., 2016). Rates of fatty acid synthesis
are governed by the expression of ATP-citrate lyase
(ACLY), acetyl-CoA carboxylase (ACC), and fatty acid
synthase (FAS) (Hanahan and Weinberg, 2011;
Hirschey et al., 2015; Shah et al., 2016; Svensson et al.,
2016; Villani et al., 2016). While AMPK may regulate
multiple branches of the lipogenic pathway, direct phos-
phorylation of ACC has been shown to result in the
inhibition of ACC activity, thereby preventing the
conversion of acetyl-CoA to malonyl-CoA and blocking
the entire lipogenic program (Fullerton et al., 2013;
Munday et al., 1988). As such, AMPK may exert
antiproliferative effects through both inhibition of lipo-
genesis and by inhibiting cell cycle progression.
Despite the many connections between AMPK and
cancer cell proliferation, mutations in the AMPK b1
subunit are not common in cancers (Forbes et al.,
2015) and recent studies have suggested that inhibition
of AMPK may make cancer cells more sensitive to
apoptosis (Jeon et al., 2012; Shackelford et al., 2013;
Zadra et al., 2015). Thus far, only one study has
examined the effects of germline deletion of AMPK in
a mouse model of tumorigenesis where the authors
observed that deletion of the AMPK a1 isoform pro-
moted B-cell lymphoma when crossed to c-Myc trans-
genic mice (Faubert et al., 2013). To the best of our
knowledge, the in vivo importance of other AMPK
subunits in combination with genetic loss of tumor-
suppressing pathways has not been studied. However,
this is important given that the 12 different AMPK
heterotrimer combinations have unique tissue-specific
expression, enzyme activities, and substrates (Ross
et al., 2016) and may have differential effects in dis-
tinct settings of oncogenesis (i.e., when interacting with
distinct tumor-promoting pathways).
The AMPK b1 isoform plays a vital role in regulat-
ing AMPK heterotrimer formation and enzyme activ-
ity in mouse liver and hematological cells such as
macrophages and T cells where it increases fatty acid
oxidation, suppresses fatty acid synthesis, and inhibits
inflammatory pathways (Blagih et al., 2015; Dzamko
et al., 2010; Fullerton et al., 2015; Galic et al., 2011).
It is also the primary subunit which is targeted by
small-molecule direct AMPK activators such as
A769662 (Cool et al., 2006; Sanders et al., 2007; Scott
et al., 2014), MT-63-78 (Zadra et al., 2014), and salicy-
late (Hawley et al., 2012), all of which have been
shown to reduce cancer cell proliferation in some
(Huang et al., 2008; O’Brien et al., 2015; Zadra et al.,
2014), but not all studies (Vincent et al., 2015). Ele-
vated AMPK b1 expression has also been linked to
increased lymphoma (Hoffman et al., 2013) and ovar-
ian cancer survival (Li et al., 2012), tumor types that
are commonly associated with mutations in p53. In
addition the DNA-damaging agent etoposide increases
AMPK b1 expression and overexpression of AMPK
b1 reduces cellular proliferation in vitro (Li et al.,
2003). However, it is not known whether AMPK b1
can inhibit tumorigenesis in vivo and in what tissues/
tumor types this may be most important.
In the current study, we generated AMPK b1-p53
null mice and found that this combined genotype
accelerates the development of a lethal T-cell lym-
phoma compared to p53 deletion alone. This increased
lethality is linked with reductions in tumor ACC phos-
phorylation and increases in interleukin 1b and lipid
synthesis. These data indicate that AMPK b1 contain-
ing complexes and AMPK activity may be important
to limit tumorigenesis and improve survival in p53-
deficient T-cell lymphomas.
2. Results
2.1. The genetic deletion of AMPK b1 accelerates
the development of T-cell lymphoma in p53-
deficient mice
To investigate the connections between AMPK and
p53 in vivo, we crossed AMPK b1 null mice (Dzamko
et al., 2010) to mice lacking p53 (Donehower et al.,
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1992). AMPK b1 null mice (Dzamko et al., 2010) were
generated on a C57Bl6 background as described and
p53 null mice had been backcrossed to a C57Bl6 back-
ground for at least 10 generations. Genetic deletion of
p53 results in the development of a T-cell lymphoma
at approximately 6 months of age (Jacks et al., 1994).
In contrast, AMPK b1 null mice have a normal lifes-
pan with no signs of elevated tumorigenesis (Dzamko
et al., 2010). The AMPK b1/ mice were born at
the expected Mendelian ratio (Fig. S1). In contrast,
the homozygous p53/ mice were born at a lower
Mendelian frequency (Fig. S1). In order to generate
the p53/ AMPK b1/ mice, we then crossed and
interbred, as described in Fig. S1, the different mice
genotypes.
Lifespan of mice was monitored over time by animal
technicians in a blinded manner. At 3 months of age,
we assessed in situ [18F]fluorodeoxyglucose (FDG)
uptake using positron emission tomography/computed
tomography (PET/CT) imaging and found that there
was a tendency for p53/ AMPK b1/ mice to
have increases in thymic FDG uptake compared to
p53/ AMPK b1+/+ mice (Fig. 1A), suggesting ear-
lier tumor onset in p53/ AMPK b1/ compared
to p53/ AMPK b1+/+ mice. Consistent with earlier
tumor onset, mice heterozygous for p53 (p53+/) or
homozygous for p53 (p53/) in the absence of
AMPK b1 had reduced survival (Fig. 1B,C). These
data indicate that AMPK b1 is important for limiting
tumor development and lethality following homozy-
gous or heterozygous deletion of the tumor suppressor
p53.
At endpoint (which was earlier in the p53/
AMPK b1/ compared to p53/ AMPK b1+/+
mice), pathological analysis indicated that both geno-
types developed a similar tumor in the thymus
(Fig. 2A). The size and weight of these tumors was
not different between genotypes at endpoint (Fig. 2A).
Both genotypes also developed a much smaller
proportion other tumors that match the tumor spec-
trum observed in the p53/ mice (Table 1) (Jacks




Fig. 1. Accelerated tumor progression in the p53/ AMPK b1/
mice. (A) Three-month-old mice were submitted to CT/PET scan,
and thymic 18F-FDG uptake was then quantified for the p53/
AMPK b1+/+ and p53/ AMPK b1/ mice. SUV, standardized
uptake values. n = 5–6 per genotypes. Results are the
means  SEM *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001 using two-tailed Student’s t-test. (B) Kaplan–Meier
survival curve showing survival of the p53+/ AMPK b1+/+ (blue)
and p53+/ AMPK b1/ (green) mice (*P < 0.05 by Wilcoxon
test). n = 6–11 mice per group. C) Kaplan–Meier survival curve
showing survival of the p53/ AMPK b1+/+ (black) and p53/
AMPK b1/ (red) mice (*P < 0.05 by Wilcoxon test). n = 13–14
mice per group.
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thymic T-cell lymphomas (Donehower et al., 1992;
Jacks et al., 1994). Therefore, we next examined two
markers of T cells (CD3 and FoxP3) and found that
expression levels were similar in the tumors of p53/
AMPK b1+/+ and 53/ AMPK b1/ mice
(Fig. 2B). Confirming these findings, immunohisto-
chemical (IHC) staining of tumor sections indicated
similar expression of the T-cell marker CD3 (Fig. 2C).
Collectively, these findings suggest that genetic deletion
of AMPK b1 does not change the tumor spectrum but
rather accelerates tumor progression.
2.2. AMPK b1 deficiency reduces ACC
phosphorylation and accelerates lipogenesis
We performed immunoblot analysis of tumor protein
extracts collected at endpoint and found that
p53/ AMPK b1/ tumors had large reductions
in total AMPK a expression and AMPK activating
phosphorylation at Thr172 (Fig. 3A–C). As
anticipated, there was no detectable p53, and impor-
tantly, there appeared to be no compensatory
increase in AMPK b2 expression (Fig. 3A). These
data indicate that tumors of p53/ AMPK b1/
mice had large reductions in AMPK activating
phosphorylation.
AMPK may regulate tumorigenesis through multiple
mechanisms so we examined phosphorylation of key
downstream substrates. One way AMPK may inhibit
tumorigenesis is through phosphorylation of ULK1 at
Ser555 and subsequent upregulation of autophagy
(Mihaylova and Shaw, 2011). There was a tendency
for a reduced ratio of pULK1 S555 to ULK1 in
tumors of p53/ AMPK b1/ mice (Fig. S2A,B).
However, there were no other signs of dysregulated
autophagy as inhibitory phosphorylation of ULK1




Fig. 2. Development of a T-cell lymphoma in the p53/ AMPK b1+/+ and p53/ AMPK b1/ mice. (A) Tumors were collected from
p53/ AMPK b1+/+ and p53/ AMPK b1/ mice at endpoint. Pictures of tumor (top). The ruler units are millimeters. Tumor sections
were stained with hematoxylin and eosin (bottom). Original magnification, 940. (B) mRNA expression of T-cell markers CD3 and FoxP3 in
tumors of p53/ AMPK b1+/+ and p53/ AMPK b1/ mice at endpoint. n = 6–7 mice per group (C) Immunohistochemical staining of
T-cell marker CD3 (original magnification, 940).
Table 1. Incidence of tumors in p53/ AMPK b1+/+ and p53/
AMPK b1/ mice. n corresponds to the total number of mice,











Incidence n % n %
Tumors
Lymphoma 16 84 17 85
Soft tissue tumors 5 26 3 15
Lymphoid leukemia 1 5
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(Fig. S2A,D) and ATG13 (Fig. S2A,E), and the ratio
of LC3BII to LC3BI (Fig. S2F,G) were all comparable
between genotypes. AMPK may also limit tumorigene-
sis by inhibiting mTOR activity (Mihaylova and Shaw,
2011), but we found that three downstream markers of
mTOR activity (S6K1 and S6 kinases and HIF1a)
were similar between genotypes (Fig. S3A–C). Activat-
ing phosphorylation of Akt was also unaltered
(Fig. S3A,D–E). As mitochondrial content is regulated
by AMPK (O’Neill et al., 2013) and has emerged as
an important factor regulating tumor progression
(Hirschey et al., 2015), we measured components of
the electron transport chain and found that they were
also comparable between p53/ AMPK b1+/+ and
p53/ AMPK b1/ mice, suggesting that tumor
mitochondrial content was not altered (Fig. S3A,F).
These data suggest reductions in autophagy and mito-
chondrial content or increases in Akt and mTOR did
not contribute to the increased tumor progression in
p53/ AMPK b1/ mice.
As AMPK b1 is important for inhibiting inflamma-
tion (Galic et al., 2011) and inflammation can
accelerate lymphoma development (Grivennikov et al.,
2011), we measured the mRNA and protein expression
of inflammatory cytokines. We found that the mRNA
and protein expression of inflammatory markers were
not altered with the exception of IL1b protein which
was elevated in tumors of p53/ AMPK b1/ mice
(Table S1). However, this increase in IL1b was not
accompanied by elevated activating phosphorylation
of c-Jun N-terminal kinase (JNK), which is known to
be downstream of the IL1 receptor (Fig. S3A,G).
There was also no difference in the activating
phosphorylation (S727 or Y705) of the signal trans-
ducer and activator of transcription 3 (STAT3)
(Fig. S3A,H,I).
Elevated rates of lipogenesis are used to fuel mem-
brane biosynthesis in rapidly proliferating cells
(Menendez and Lupu, 2007; Zadra et al., 2014). ACC
is an important enzyme regulating lipogenesis and is
inhibited by AMPK following phosphorylation at
Ser79 (Fullerton et al., 2013; Munday et al., 1988). We
found that consistent with reductions in AMPK acti-
vating phosphorylation, there was a reduction of
approximately 50% in phosphorylation of ACC at
Ser79 compared to the p53/ AMPK b1+/+ tumors
(Fig. 4A,B). There were no alterations in the expres-
sion of other lipogenic enzymes [acetyl-CoA synthetase
(ACCSS2), malonyl-CoA decarboxylase (MCD), ATP-
citrate lyase (ACLY), fatty acid synthase (FASN), and
phosphorylation of S372 on sterol regulatory element-
binding protein 1c (SREBP1c)]. Consistent with
reductions in ACC phosphorylation, we measured
in vivo lipogenesis in 3-month-old mice and found that
p53/ AMPK b1/ mice tended to have an
increased incorporation of acetate into fatty acids
compared to p53/ AMPK b1+/+ mice (Fig. 4C).
These data indicate that genetic deletion of AMPK b1
leads to reductions in ACC phosphorylation and tends
to increase de novo lipogenesis in vivo.
To further examine the mechanisms by which
lipogenesis may regulate cellular proliferation, we gen-
erated mouse embryonic fibroblasts (MEFs) from
p53/ AMPK b1+/+ and p53/ AMPK b1/ lit-
termates. Consistent with immunoblotting in tumors,
we found that p53/ AMPK b1/ MEFs
(Fig. 4D) had reductions in AMPK and ACC phos-
phorylation (Fig. 4D–G), but not alterations in the
expression of other regulators of lipogenesis (ACSS2,
MCD, ACLY, FASN, pSREBP1c, Fig. 4D). Similar
to observations in the tumor, this reduction in ACC
phosphorylation was associated with a significant
A B C
Fig. 3. Impaired AMPK phosphorylation in tumors harvested from the p53/ AMPK b1/ mice. (A) Tumors harvested from p53/
AMPK b1+/+ and p53/ AMPK b1/ mice were homogenized and subjected to immunoblotting using the indicated antibodies. Six
animals per genotype are shown. A thymus from a WT mouse was used as a control. Bar graphs show densitometry of (B) AMPKa/b-actin,
C) pAMPKa Thr172/b-actin. Results are the means  SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 using two-tailed Student’s
t-test.
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Fig. 4. AMPK b1 deficiency accelerates lipogenesis. (A) Tumors harvested from p53/ AMPK b1+/+ and p53/ AMPK b1/ mice were
homogenized and subjected to immunoblotting using the indicated antibodies. Six animals per genotype are shown. A thymus from a WT
mouse was used as a control. Bar graphs show densitometry of (B) pACC Ser79/ACC immunoblots. (C) In vivo lipogenesis in p53/
AMPK b1+/+ and p53/ AMPK b1/ mice. n = 5–8 mice per genotype. (D) p53/ AMPK b1+/+ and p53/ AMPK b1/ MEFs were
subjected to immunoblotting with the indicated antibodies. Bar graphs show densitometry of (E) ACC/b-actin, (F) pACC Ser79/ACC, and (G)
pAMPKa Thr172/b-actin immunoblots. n = 2–3 independent experiments in duplicate. (H) Lipogenesis in p53/ AMPK b1+/+ and p53/
AMPK b1/ MEFs. n = 3 independent experiments in triplicate. (I) Cell proliferation was measured in p53+/+ AMPK b1+/+ and ACC DKI
MEFs. n = 4 independent experiments. p53/ AMPK b1/ MEFs were treated with increasing concentrations of (J) TOFA and (K) C75,
and cell proliferation was then measured. n = 2–3 independent experiments. Results are the means  SEM. *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001 using two-tailed Student’s t-test (for A–I) and one-way ANOVA and Fisher’s post hoc test (for J,K).
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increase in lipogenesis (Fig. 4H). These data suggest
that reduced AMPK-mediated phosphorylation of
ACC was important for increasing lipogenesis and the
subsequent proliferative capacity of p53/ AMPK
b1/ mice via a cell autonomous pathway.
To directly evaluate the importance of AMPK
phosphorylation of ACC in regulating cellular prolifer-
ation, we examined MEFs derived from mice with
Ser-Ala-knock-in mutations in the AMPK phosphory-
lation site on ACC1 (S79A) and ACC2 (S212A) (ACC
DKI), which makes ACC constitutively active and
increases rates of lipogenesis (Fullerton et al., 2013).
We found that MEFs derived from ACC DKI mice
had increased proliferation rates by 1.9-fold compared
to WT controls (Fig. 4I), indicating that AMPK regu-
lation of ACC phosphorylation is vital for limiting cel-
lular proliferative capacity. To further examine the
importance of lipogenesis in regulating cellular prolif-
eration, we treated MEFs with TOFA and C75, two
inhibitors of lipogenesis that act downstream of
AMPK b1 to inhibit ACC and fatty acid synthase
activity, respectively, and found that both agents dose
dependently inhibited cellular proliferation (Fig. 4J,K).
Collectively, these data suggest that AMPK b1 inhibi-
tion of lipogenesis, through phosphorylation of ACC,
may be important for limiting proliferation in the
absence of p53.
3. Discussion
Reductions in AMPK activity can occur under a num-
ber of pathological conditions known to increase can-
cer incidence. These include inactivating mutations in
the tumor suppressors p53 and LKB1 or elevated
levels of glucose (Friedrichsen et al., 2013), insulin
(Ruderman et al., 2013), TNF (Steinberg et al., 2006),
and LPS (Galic et al., 2011). In contrast, elevated
levels of AMPK b1 have been associated with
increased survival in lymphoma and ovarian cancer
(Hoffman et al., 2013; Li et al., 2012). In the current
study, we provide the first genetic evidence that dele-
tion of the AMPK b1 isoform accelerates the progres-
sion of a T-cell lymphoma that reduces the survival of
mice that are heterozygous or homozygous null for
p53. Interestingly, the deletion of AMPK b1 did not
alter the spectrum of cancer development compared to
p53 deficiency alone, in that both mice still developed
T-cell lymphoma. This may be because AMPK b1 is
the predominant subunit expressed in the thymus and
hematopoietic tissues and hence these tissues, which
are also the most sensitive to the loss of p53, also had
the greatest reduction in AMPK activity. While our
findings may only be applicable to T-cell lymphoma, it
is intriguing to speculate that because p53 loss-of-func-
tion mutations are associated with approximately 80%
of all cancers, these findings may be applicable to
other types of cancer where the AMPK b1 subunit
predominates, such as the liver, lung, gastrointestinal
tract, or ovaries.
Previous studies by Faubert et al. (2013) found that
genetic deletion of AMPK a1 accelerates Myc-driven
lymphoma due to elevations in mTORC1 activity and
subsequent increases in HIF1a that promoted aerobic
glycolysis (Warburg effect). In contrast to these find-
ings, we found that AMPK b1-p53 null tumors did
not have altered activity of mTORC1 (as detected by
normal phosphorylation of downstream substrates
S6K, S6, and ULK1 S757) or HIF1a. We also
detected no change in markers of autophagy or mito-
chondrial content. Instead, we found that AMPK b1
p53 null tumors and MEFs had increased rates of lipo-
genesis that was not associated with alterations in the
expression of fatty acid synthetic enzymes but instead
was directly related to reduced phosphorylation of
ACC. Proliferation data from the ACC DKI MEFs or
cells treated with lipogenesis inhibitors corroborated
these results, suggesting that AMPK control of lipoge-
nesis, through ACC inhibition, is important for limit-
ing cellular proliferation. These data are in agreement
with previous studies indicating that hepatocytes
(Dzamko et al., 2010) and macrophages (Fullerton
et al., 2015) from AMPK b1-deficient mice have
increased lipid synthesis and that activation of AMPK
using A769662 or metformin lowers lipogenesis
through an AMPK b1-dependent pathway requiring
the phosphorylation of ACC (Fullerton et al., 2013).
These data are also consistent with recent studies indi-
cating that inhibiting lipogenesis, by mimicking
AMPK phosphorylation of ACC using small mole-
cules (Svensson et al., 2016) or through chemical inhi-
bition of fatty acid synthase (Menendez and Lupu,
2007; Orita et al., 2008), is effective for limiting cellu-
lar proliferation. However, it is possible that the inhi-
bition of proliferation is not directly related to the
blunting of lipid synthesis but rather a buildup of mal-
onyl-CoA or some other metabolite. Furthermore,
under conditions of metabolic stress that are common
within the tumor microenvironment, it is possible that
increases in lipid synthesis may be toxic for tumor sur-
vival as previously described (Jeon et al., 2012). Future
studies in mice lacking p53 and ACC1 S79 and ACC2
S212 phosphorylation are required to directly establish
the importance of this lipogenic pathway in limiting
proliferation and survival.
In addition to increases in lipogenesis, we also
detected elevated IL1b protein (but not other
1149Molecular Oncology 11 (2017) 1143–1155 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
V. P. Houde et al. AMPK b1 improves survival in p53 null mice
inflammatory proteins) in AMPK b1p53 null tumors.
In contrast to other inflammatory cytokines (e.g.,
TNFa, IL6), increases in IL1b protein are the result of
the induction of the NLRP3 (NOD-like receptor fam-
ily, pyrin domain containing) inflammasome pathway
(Haneklaus et al., 2013; Steinberg and Schertzer,
2014). Production of bioactive IL1b by the NLRP3
inflammasome requires a two-step process involving
initial priming from the toll-like receptors (TLR) by
lipopolysaccharide (LPS) and subsequent activation by
hyperglycemia, saturated fatty acids such as palmitate,
ROS, oxidized LDL, or cholesterol crystals. This leads
to NLRP3 assembly with a protein complex containing
caspase-1 and consequent processing and secretion of
mature IL1b (Haneklaus et al., 2013; Steinberg and
Schertzer, 2014). Importantly, the NLRP3 inflamma-
some can be inhibited by AMPK (Wen et al., 2011),
although the mechanisms are not fully understood [for
review, see (Steinberg and Schertzer, 2014)]. So while
the role of IL1b in tumorigenesis is context dependent
and is largely dependent on the tumor microenviron-
ment, it is possible that AMPK inhibition of the
NLRP3 inflammasome may also be important for
reducing tumorigenesis in p53 null mice. However,
future studies are required to directly investigate this
concept.
Our study had several limitations. First, we did not
examine the morphology of tumors before endpoint.
Earlier analysis of tumors could have potentially led to
detectable differences in signaling pathways, histology,
and tumor sizes between genotypes. Consistent with
this idea, there were strong tendencies for increases in
both FDG uptake and lipogenesis in p53/ AMPK
b1/ mice at 12 weeks of age, which was 6–10 weeks
before endpoint. Another limitation of our study was
that we did not examine the effects of AMPK b1 dele-
tion specifically in T cells. This means that increases in
tumorigenesis and reduced survival in p53/ AMPK
b1/ could have been due to other factors besides
the primary lesion. For example, AMPK a1, b1, and
c1 null mice have been shown to have increased red
blood cell fragility, which causes microcytic anemia
and splenomegaly without altering the number of
leukocytes (Cambridge et al., 2017; F€oller et al., 2009;
Foretz et al., 2010, 2011). We also observed splenome-
galy in our AMPK b1 null mice (Table S2) so it is
possible that this could have an impact on tumorigene-
sis and lifespan of p53/ AMPK b1/ mice.
Future studies investigating deletion of AMPK b1 and
p53 specifically in T cells will be important for
establishing the exact tissues contributing to the accel-
erated tumorigenesis and reduced longevity of p53/
AMPK b1/ mice.
In conclusion, our studies provide the first in vivo
evidence for a role of the AMPK b1 isoform in limit-
ing the progression of tumorigenesis that results from
a deficiency in p53. Increased tumorigenesis in this
model was associated with reduced AMPK phosphory-
lation of ACC and elevated IL1b and lipogenesis, indi-
cating that the maintenance of AMPKb1 expression is
important for limiting the progression of p53-deficient
tumors.
4. Materials and methods
4.1. Materials
Complete protease inhibitor cocktail tablets were
obtained from Roche (Laval, QC, Canada). [3H]Acetic
acid was from PerkinElmer (Waltham, MA, USA).
Cell culture media and reagents were from Life Tech-
nologies (Burlington, ON, Canada). TOFA (5-(tetrade-
cyloxy)-2-furoic acid) and C75 ((2R*,3S*)-tetrahydro-
4-methylene-2-octyl-5-oxo-3-furancarboxylic acid) were
purchased from Cayman Chemical (Ann Arbor, MI,
USA). All other chemicals were purchased from Sigma
(St. Louis, MO, USA).
4.2. Antibodies
The anti-phospho-ACC S79 (catalogue # 3661), anti-
ACC (catalogue # 3676), anti-phospho-AMPKa
Thr172 (catalogue # 2535), anti-AMPKa (catalogue
# 2532), anti-AMPK b1/b2 (catalogue # 4150), anti-
p53 (catalogue # 2524), anti-b-actin (catalogue #
5125), anti-acetyl-CoA synthetase (ACSS2) (catalogue
# 3658), anti-pULK1 S555 (catalogue # 5569), anti-
phospho-ULK1 S757 (catalogue # 6888), anti-ULK1
(catalogue # 8054), anti-p62 (catalogue # 5114), anti-
ATG13 (catalogue # 6940), anti-LC3B (catalogue #
3868), anti-phospho-S6K1 Thr389 (catalogue #
9205), anti-S6K1 (catalogue # 9202), anti-phospho-S6
S240/244 (catalogue # 5364), anti-S6 (catalogue #
2217), anti-phospho-Akt S473 (catalogue # 4058),
anti-phospho-Akt Thr308 (catalogue # 4056), anti-
Akt (catalogue # 9272), anti-ATP-citrate lyase
(ACLY) (catalogue # 4332), anti-fatty acid synthase
(Fasn) (catalogue # 3189), anti-phospho-sterol regula-
tory element-binding protein 1c-S372 (SREBP1c)
(catalogue # 9874), anti-HIF1a (catalogue # 3716),
anti-phospho-c-Jun N-terminal kinase Thr183/Y185
(JNK) (catalogue # 4668), anti-phospho-signal trans-
ducer and activator of transcription 3 S727 (STAT3)
(catalogue # 9134), and anti-phospho-STAT3 Y705
(catalogue # 9145) were purchased from Cell Signal-
ing Technology (Danvers, MA, USA). Malonyl-CoA
1150 Molecular Oncology 11 (2017) 1143–1155 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
AMPK b1 improves survival in p53 null mice V. P. Houde et al.
decarboxylase (MCD) (catalogue # ab95945) anti-
body was purchased from Abcam (Cambridge, MA,
USA). The anti-CD3 (MRQ-39) antibody used for
immunohistochemistry was from CELL MARQUE
(Rocklin, CA, USA). The anti-OXPHOS antibody
was purchased from MitoSciences (Eugene, OR,
USA). The anti-secondary antibodies coupled to
HRP (horseradish peroxidase) were from Cell Signal-
ing Technology.
4.3. Generation of p53/ AMPK b1/ mice
All experiments were approved by the McMaster
University Animal Ethics Committee and conducted
under the Canadian guidelines for animal research.
Animals were housed in microisolator cages located in
a room maintained at 23 °C with a 12-h light/dark
cycle and fed with normal chow diet ad libitum.
p53+/ mice on a C57BL/6 background were pur-
chased from The Jackson Laboratory (B6.129S2-
Trp53tm1Tyj/J, stock 002101; Bar Harbor, ME, USA).
AMPK b1 null mice (Dzamko et al., 2010) were gener-
ated on a C57Bl6 background as described and p53
null mice had been backcrossed to a C57Bl6 back-
ground for at least 10 generations. Heterozygous mice
(p53+/) were interbred to generate p53/ and
p53+/+ littermates. The p53/ mice were then
crossed with the AMPK b1/ mice (Dzamko et al.,
2010) to generate the p53+/ AMPK b1+/ mice.
These mice were then interbred to generate the p53/
 AMPK b1/ mice on a C57Bl6 background.
Lifespan was determined in a blinded manner by an
animal technician who monitored whether mice were
found dead or whether mice had reached endpoint
according to established parameters [weight loss
(>20%), hunched posture, lethargy, labored breathing].
Routine pathology analysis of formalin-fixed tissues
harvested from mice culled at endpoint was performed
at the Department of Pathobiology, Ontario Veteri-
nary College, University of Guelph (Ontario, Canada).
4.4. Generation of MEFs
p53/ AMPK b1+/+, p53/ AMPK b1/, and
ACC DKI (S79A in ACC1 and S212A in ACC2)
MEFs isolated from mouse embryos at E13.5 (em-
bryonic day 13.5) were generated as described previ-
ously (Houde et al., 2014) and immortalized by
continuous passaging. Cells were cultured in DMEM
(25 mM glucose) containing 10% FBS, 4 mM L-
glutamine, 1 mM sodium pyruvate, 1X antibiotic/an-
timycotic solution, and 1X nonessential amino acids
solution.
4.5. Mouse imaging
[18F]Fluorodeoxyglucose (FDG) was synthesized at
McMaster University and injected into three-
month-old male mice as previously described (Palani-
vel et al., 2012). FDG uptake was quantified as
described (Crane et al., 2015).
4.6. Cell proliferation
5 9 102 cells per well were seeded on 96-well plate and
grown for 5 days before being fixed with 10% forma-
lin, stained with 0.5% crystal violet, washed with H2O,
and dried at 37 °C. The crystal violet was then solubi-
lized with 0.05 M NaH2PO4 and the absorbance mea-
sured at 570 nm as described (O’Brien et al., 2015).
Proliferation rate was compared from untreated p53+/+
AMPK b1+/+ and ACC DKI MEFs. p53/ AMPK
b1/ MEFs were also treated with TOFA and
C75 at the indicated concentrations 24 h after seed-
ing, and proliferation was monitored as described
above.
4.7. Immunoblotting
Cells were washed with PBS and lysed in ice-cold lysis
buffer (20 mM Tris/HCl, 150 mM NaCl, 1 mM EDTA,
1 mM EGTA, 1% Triton X-100, 2.5 mM Na4O7P2, 1 mM
Na3VO4, and Roche inhibitor cocktail). Tissues were
homogenized on ice using a Polytron in a 10-fold mass
excess of ice-cold lysis buffer. Lysates were clarified by
centrifugation at 19 000 g for 15 min at 4 °C. Protein
concentrations were measured with a BCA assay. Tissue
or cell lysates (10–20 lg) were heated in SDS sample
buffer and subjected to SDS/PAGE followed by electro-
transfer on to nitrocellulose membranes. Membranes
were blocked in TBST [50 mM Tris/HCl (pH 7.5),
0.15 mM NaCl, and 0.1% Tween] containing 5% BSA
for 1 h. The membranes were then probed with the pri-
mary antibody (1000-fold dilution) for 16 h at 4 °C in
TBST 5% BSA. Detection of protein was performed
using HRP-conjugated secondary antibodies and an
ECL reagent. Immunoblots were analyzed using IMAGEJ
software (NIH, Bethesda, MD, USA).
4.8. Measurement of lipogenesis
In vitro, cells were labeled for 4 h with 0.5 mM sodium
acetate and 10 lCi mL1 [3H]acetic acid in growth
media. Cells were washed three times with ice-cold
PBS and then scraped into chilled PBS. Cells were pel-
leted by centrifugation at 2000 g for 2 min. A metha-
nol/chloroform lipid extraction was performed on the
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cell pellets. After the extraction, the insoluble material
(pellet) was dissolved in 0.5 M NaOH/0.5% SDS in
order to quantify the amount of protein per well. The
incorporation of [3H] into the lipid was measured by
scintillation counting. The incorporation rate was
defined in units of nmol of acetate/mg of protein/h.
In vivo, 12-week-old mice were fasted for 16 h and
refed for 2 h. 20 lCi of [3H]acetic acid was then
injected intraperitoneally (IP) for 1 h. De novo lipogen-
esis was determined in vivo by the incorporation of
[3H]acetate into thymic lipids.
4.9. Immunohistochemistry lymphoma
Formalin-fixed and paraffin-embedded 5-lm sections
were stained with hematoxylin and eosin or an anti-
CD3 antibody (Pearse, 2006), using BENCHMARK
ULTRA VENTANA accordingly to the manufac-
turer’s instructions (Roche).
4.10. mRNA expression
For mRNA analysis, tissues were lysed in TRIzol
reagent (Life Technologies) and RNA was extracted
for qRT-PCR and mRNA assessed as described (Galic
et al., 2011).
4.11. Enzyme-linked immunosorbent assay
Tumors (50–100 mg) were homogenized on ice using a
Polytron in ice-cold lysis buffer 2 (catalogue # 895347,
R&D Systems, Minneapolis, MN, USA) containing
Roche inhibitor cocktail. Lysates were clarified by cen-
trifugation at 19 000 g for 15 min at 4 °C. Protein
concentrations were measured with a BCA assay.
500 lg of protein lysate was then used to measure
IFNc (Quantikine, R&D Systems), IL6, IL1b, and
TNFa (DuoSet, R&D Systems) according to the man-
ufacturer’s instructions.
4.12. Statistical analysis
Results are expressed as mean  SEM. Statistical
analyses were performed using two-tailed Student’s t-
test or one-way ANOVA when appropriate. Fisher’s
least significant difference was used. Significance was
set at *P < 0.05 using GRAPHPAD PRISM 6 software (La
Jolla, CA, USA).
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